XNYS
LH
Market cap25bUSD
Oct 08, Last price
314.20USD
1D
0.71%
1Q
13.51%
Jan 2017
184.88%
Name
Laboratory Corporation of America Holdings
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Labcorp Holdings, Inc. delivers specialized diagnostic laboratory services. Its purpose is to empower a diverse group of stakeholders – including medical professionals, hospitals, pharmaceutical companies, scientific researchers, and individual patients – to arrive at well-informed and confident decisions. The organization commenced operations on April 16, 2024, and conducts its central management from its headquarters in Burlington, North Carolina.
Related entities
Subsidiaries (10)
CHILTERN INTERNATIONAL LIMITED
CLEARSTONE HOLDINGS (INTERNATIONAL) LTD
Dynacare Company
FORTREA DEVELOPMENT LIMITED
Labcorp Central Laboratory Services GmbH
LABCORP CLINICAL RESEARCH UNIT LIMITED
LABCORP EARLY DEVELOPMENT LABORATORIES LIMITED
Labcorp International Holdings B.V.
LABCORP INTERNATIONAL HOLDINGS LIMITED
COVANCE LIMITED
Key people
Chairman of the Board, President, Chief Executive Officer · since 2020
Chief Financial Officer, Executive Vice President · since 2014
President, Chief Executive Officer - Clinical Development Business Unit · since 2023
Chief Human Resources Officer, Executive Vice President · since 2023
Megan Bailey
Executive Vice President, Chief Strategy and Transformation Officer · since 2023
Brian Caveney
Executive Vice President, President, Early Development, Chief Medical and Scientific Officer · since 2023
Executive Vice President, President, Central Laboratories and International · since 2023
Mark Schroeder
Executive Vice President, President - Diagnostics Laboratories, Chief Operations Officer · since 2023
Peter Wilkinson
Senior Vice President, Chief Accounting Officer · since 2019
Lance Berberian
Executive Vice President, Chief Information and Technology Officer · since 2020
Amy Summy
Executive Vice President, Chief Marketing Officer · since 2020
Sandra van Der Vaart
Executive Vice President, Chief Legal Officer, Chief Compliance Officer, Corporate Secretary · since 2020
Independent Director · since 2006
Jeffrey Davis
Independent Director · since 2019
D. Gary Gilliland
Independent Director · since 2014
Independent Director · since 2022
Lead Independent Director · since 2023
Independent Director · since 2023
Independent Director · since 2016
Paul Rothman
Independent Director · since 2023
Legal address
251 LITTLE FALLS DRIVE
WILMINGTON, DE 19808
US
WILMINGTON, DE 19808
US
Headquarters
2626 Glenwood Avenue, Suite 550
Raleigh, NC 27608
US
Raleigh, NC 27608
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||